At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 08 Feb 2001 Profile reviewed but no significant changes made
- 17 Jun 1998 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 06 Dec 1994 Preclinical development for Hyperlipidaemia in USA (Unknown route)